Eliezer Shochat

909 total citations
17 papers, 588 citations indexed

About

Eliezer Shochat is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Eliezer Shochat has authored 17 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 3 papers in Genetics. Recurrent topics in Eliezer Shochat's work include Melanoma and MAPK Pathways (5 papers), Neutropenia and Cancer Infections (4 papers) and Mathematical Biology Tumor Growth (3 papers). Eliezer Shochat is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Neutropenia and Cancer Infections (4 papers) and Mathematical Biology Tumor Growth (3 papers). Eliezer Shochat collaborates with scholars based in Switzerland, Israel and United Kingdom. Eliezer Shochat's co-authors include Zvia Agur, Deborah R. Hart, Vered Rom‐Kedar, Lewi Stone, Svetlana Bunimovich‐Mendrazitsky, Jean Tessier, Françoise Kraeber‐Bodéré, Lee A. Segel, Ruediger Rueger and Zhixin Xu and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Eliezer Shochat

17 papers receiving 563 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eliezer Shochat Switzerland 12 302 234 187 73 63 17 588
Amanda Tracz United States 10 283 0.9× 227 1.0× 222 1.2× 61 0.8× 42 0.7× 14 679
Amin Yaqubie United States 6 289 1.0× 209 0.9× 91 0.5× 31 0.4× 59 0.9× 15 578
Irina Kareva United States 16 307 1.0× 362 1.5× 171 0.9× 178 2.4× 85 1.3× 44 836
Hiroshi Haeno Japan 13 447 1.5× 468 2.0× 142 0.8× 110 1.5× 47 0.7× 29 1.0k
Yuri Kogan Israel 14 248 0.8× 317 1.4× 362 1.9× 162 2.2× 36 0.6× 33 626
Fee Klupp Germany 11 232 0.8× 295 1.3× 57 0.3× 106 1.5× 20 0.3× 19 548
Ariosto S. Silva United States 12 479 1.6× 303 1.3× 339 1.8× 62 0.8× 187 3.0× 21 1.1k
Moran Elishmereni Israel 15 154 0.5× 245 1.0× 257 1.4× 301 4.1× 19 0.3× 20 753
Christopher D. McFarland United States 9 443 1.5× 143 0.6× 77 0.4× 35 0.5× 211 3.3× 14 693
S Michelson United States 13 170 0.6× 148 0.6× 192 1.0× 17 0.2× 31 0.5× 29 410

Countries citing papers authored by Eliezer Shochat

Since Specialization
Citations

This map shows the geographic impact of Eliezer Shochat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eliezer Shochat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eliezer Shochat more than expected).

Fields of papers citing papers by Eliezer Shochat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eliezer Shochat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eliezer Shochat. The network helps show where Eliezer Shochat may publish in the future.

Co-authorship network of co-authors of Eliezer Shochat

This figure shows the co-authorship network connecting the top 25 collaborators of Eliezer Shochat. A scholar is included among the top collaborators of Eliezer Shochat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eliezer Shochat. Eliezer Shochat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Baruch, Kuti, et al.. (2020). IBC‐Ab002, an anti‐PD‐L1 monoclonal antibody tailored for treating Alzheimer’s disease. Alzheimer s & Dementia. 16(S9). 2 indexed citations
2.
Nowak, Radosław P., Erica Lorenzon, Markus Thomas, et al.. (2015). An integrated approach to quantitative modelling in angiogenesis research. Journal of The Royal Society Interface. 12(110). 20150546–20150546. 19 indexed citations
3.
Johnson, David, Steve McKeever, Zhihui Wang, et al.. (2014). Semantically Linking in Silico Cancer Models. Cancer Informatics. 13s1(Suppl 1). CIN.S13895–CIN.S13895. 8 indexed citations
4.
5.
Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2012). Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(17). 4794–4805. 55 indexed citations
6.
Martinez‐García, Maria, Udai Banerji, Joan Albanell, et al.. (2012). First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. Clinical Cancer Research. 18(17). 4806–4819. 122 indexed citations
7.
Kraeber‐Bodéré, Françoise, Thomas Carlier, Eliezer Shochat, et al.. (2012). Differences in the Biologic Activity of 2 Novel MEK Inhibitors Revealed by 18F-FDG PET: Analysis of Imaging Data from 2 Phase I Trials. Journal of Nuclear Medicine. 53(12). 1836–1846. 20 indexed citations
8.
Wolach, Baruch, et al.. (2012). Evidence for bistable bacteria-neutrophil interaction and its clinical implications. Journal of Clinical Investigation. 122(8). 3002–3011. 18 indexed citations
9.
Leijen, Suzanne, Mark R. Middleton, Patricia Tresca, et al.. (2011). Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced /metastatic solid tumor.. Journal of Clinical Oncology. 29(15_suppl). 3017–3017. 7 indexed citations
10.
Dolly, Saoirse, Joan Albanell, Françoise Kraeber‐Bodéré, et al.. (2011). First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3006–3006. 4 indexed citations
11.
Shochat, Eliezer, et al.. (2010). Bistability and Bacterial Infections. PLoS ONE. 5(5). e10010–e10010. 19 indexed citations
12.
Shochat, Eliezer & Vered Rom‐Kedar. (2008). Novel Strategies for Granulocyte Colony-Stimulating Factor Treatment of Severe Prolonged Neutropenia Suggested by Mathematical Modeling. Clinical Cancer Research. 14(20). 6354–6363. 21 indexed citations
13.
Bunimovich‐Mendrazitsky, Svetlana, Eliezer Shochat, & Lewi Stone. (2007). Mathematical Model of BCG Immunotherapy in Superficial Bladder Cancer. Bulletin of Mathematical Biology. 69(6). 1847–1870. 72 indexed citations
14.
Shochat, Eliezer, Vered Rom‐Kedar, & Lee A. Segel. (2007). G-CSF Control of Neutrophils Dynamics in the Blood. Bulletin of Mathematical Biology. 69(7). 2299–2338. 39 indexed citations
15.
Shochat, Eliezer. (2002). Human Haematopoiesis in Steady State and Following Intense Perturbations. Bulletin of Mathematical Biology. 64(5). 861–886. 26 indexed citations
16.
Shochat, Eliezer, Deborah R. Hart, & Zvia Agur. (1999). USING COMPUTER SIMULATIONS FOR EVALUATING THE EFFICACY OF BREAST CANCER CHEMOTHERAPY PROTOCOLS. Mathematical Models and Methods in Applied Sciences. 9(4). 599–615. 34 indexed citations
17.
Hart, Deborah R., Eliezer Shochat, & Zvia Agur. (1998). The growth law of primary breast cancer as inferred from mammography screening trials data. British Journal of Cancer. 78(3). 382–387. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amanda Tracz Breakdown of academic impact, for papers by Amin Yaqubie Breakdown of academic impact, for papers by Irina Kareva Breakdown of academic impact, for papers by Hiroshi Haeno Breakdown of academic impact, for papers by Yuri Kogan Breakdown of academic impact, for papers by Fee Klupp Breakdown of academic impact, for papers by Ariosto S. Silva Breakdown of academic impact, for papers by Moran Elishmereni Breakdown of academic impact, for papers by Christopher D. McFarland Breakdown of academic impact, for papers by S Michelson
Rankless by CCL
2026